Internal medicine, Endocrinology, Insulin, Pancreatic hormone and Diabetes mellitus are his primary areas of study. He performs multidisciplinary study on Internal medicine and Crossover study in his works. His work is connected to Type 2 diabetes, Glucose uptake, Basal, Liraglutide and Carbohydrate metabolism, as a part of Endocrinology.
His work on Insulin resistance, Glucagon, Glucose tolerance test and Glucose clamp technique as part of general Insulin study is frequently connected to Lipid oxidation, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His Pancreatic hormone study combines topics from a wide range of disciplines, such as Blood plasma, Signal transduction, Cell biology and Somatostatin. His Impaired glucose tolerance study also includes
Ole Schmitz mainly investigates Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Insulin resistance. His Internal medicine study frequently draws connections to adjacent fields such as Type 2 diabetes. His work deals with themes such as Metformin, Obesity and Type 2 Diabetes Mellitus, which intersect with Type 2 diabetes.
His Insulin research incorporates elements of Somatostatin and Skeletal muscle. The various areas that he examines in his Diabetes mellitus study include Myocardial infarction and Cardiology. His biological study spans a wide range of topics, including Adipose tissue, First-degree relatives and VO2 max.
Ole Schmitz mostly deals with Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Insulin resistance. His work on Internal medicine is being expanded to include thematically relevant topics such as Type 2 diabetes. His Type 2 diabetes research is multidisciplinary, relying on both Metformin, Obesity, Randomized controlled trial, Reverse cholesterol transport and Hepatic lipase.
In the subject of general Insulin, his work in Glucagon, C-peptide and Pancreatic hormone is often linked to Crossover study, thereby combining diverse domains of study. His Diabetes mellitus study combines topics in areas such as Cholesterol, Surgery and Myocardial infarction, Cardiology. In his research, Phenylalanine, Tyrosine and Epinephrine is intimately related to Metabolism, which falls under the overarching field of Insulin resistance.
His primary scientific interests are in Internal medicine, Endocrinology, Type 2 diabetes, Insulin and Diabetes mellitus. His study in Internal medicine is interdisciplinary in nature, drawing from both Glucagon-like peptide-1 and Surgery. His Carbohydrate metabolism, Pancreatic islets and Blood pressure study, which is part of a larger body of work in Endocrinology, is frequently linked to Zinc, bridging the gap between disciplines.
His Type 2 diabetes research includes themes of Metformin, Odds ratio, Physiology and Insulin resistance. His work in the fields of Glycemic overlaps with other areas such as Crossover study. He has included themes like Hazard ratio and Cardiology in his Diabetes mellitus study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy;Bernard Charbonnel;David J A Eckland;Erland Erdmann.
The Lancet (2005)
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones;A. Vaag;O. Schmitz;B. K. Sethi.
Effect of valsartan on the incidence of diabetes and cardiovascular events.
John McMurray;R Holman;Steven Haffner;M Bethel.
The New England Journal of Medicine (2010)
Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
Tina Vilsbøll;Milan Zdravkovic;Tu Le-Thi;Thure Krarup.
Diabetes Care (2007)
Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin
S Lund;G D Holman;O Schmitz;O Pedersen.
Proceedings of the National Academy of Sciences of the United States of America (1995)
One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes
Kristine B. Degn;Claus B. Juhl;Jeppe Sturis;Grethe Jakobsen.
Effect of nateglinide on the incidence of diabetes and cardiovascular events
Rury R. Holman;Steven M. Haffner;Steven M. Haffner;John J. McMurray;M. Angelyn Bethel;M. Angelyn Bethel.
The New England Journal of Medicine (2010)
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Sten Madsbad;Ole Schmitz;Jonas Ranstam;Grethe Jakobsen.
Diabetes Care (2004)
Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants
Yingrui Li;Nicolas Vinckenbosch;Geng Tian;Emilia Huerta-Sanchez.
Nature Genetics (2010)
Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes
Claus B. Juhl;Malene Hollingdal;Jeppe Sturis;Grethe Jakobsen.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: